Description:

This is a Phase 3 Study for PRIMARY PROGRESSIVE MS Patients, aged 18-55, who are still ambulatory (can be with cane or walker). Ocrelizumab is a drug similar to rituximab that depletes circulating B cells. It is a humanized monoclonal against CD20 which is expressed only on B cells. In an earlier study, rituximab (a chimeric monoclonal antibody against CD20) showed much promise in the subset of younger PPMS patients [Hawker et al. Ann Neurol. 66:460-71, 2009].

2/3 of enrolled subjects will receive active ocrelizumab, and 1/3^rd will receive placebo.

Inclusion Criteria: PPMS still able to walk (can be with assistance), aged 55 or younger.

Length of Trial: 2.5 years, with open-label extension.

WHO IS THE PRINCIPAL INVESTIGATOR?

Anne H. Cross, MD
660 South Euclid Avenue
Campus Box 8111
Saint Louis, MO 63110

Contact:

Susan Fox, Clinical Coordinator

We will need medical records documenting diagnosis of MS, MRI reports, CSF results (if done).

Fax to attention of Susan Fox at 314-747-1345

Location of Trial: John L. Trotter MS Center

Washington University School of Medicine
517 S. Euclid
St. Louis, MO 63110

Clinical Trial Sponsor:

Roche